News Releases

March 2021

March 3, 2021 3/3/2021 Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

February 2021

February 26, 2021 2/26/2021 Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited

February 24, 2021 2/24/2021 Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan

February 12, 2021 2/12/2021 Takedas Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory With or Without Resistance Cytomegalovirus Infection Disease

February 10, 2021 2/10/2021 Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease

February 4, 2021 2/4/2021 Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)

February 4, 2021 2/4/2021 Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPS

February 3, 2021 2/3/2021 Data at EAHAD 2021 Highlight Value of Takeda’s Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements

February 1, 2021 2/1/2021 Takeda Completes Sale of TachoSil® to Corza Health